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Abstract
Background: The use of intravascular lithotripsy (IVL) in chronic total occlusion
(CTO) percutaneous coronary intervention (PCI) has received limited study.
Methods: We analyzed the baseline clinical and angiographic characteristics and
procedural outcomes of 82 CTO PCIs that required IVL at 14 centers between 2020
and 2022.
Results: During the study period, IVL was used in 82 of 3301 (2.5%) CTO PCI
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procedures (0.4% in 2020 and 7% in 2022; p for trend < 0.001). Mean patient age
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was 69 ± 11 years and 79% were men. The prevalence of hypertension (95%),
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diabetes mellitus (62%), and prior PCI (61%) was high. The most common target
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vessel was the right coronary artery (54%), followed by the left circumflex (23%). The
mean J‐CTO and PROGRESS‐CTO scores were 2.8 ± 1.1 and 1.3 ± 1.0, respectively.
Antegrade wiring was the final successful crossing strategy in 65% and the
retrograde approach was used in 22%. IVL was used in 10% of all heavily calcified
lesions and 11% of all balloon undilatable lesions. The 3.5 mm lithotripsy balloon was
the most commonly used balloon (28%). The mean number of pulses per lithotripsy
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run was 33 ± 32 and the median duration of lithotripsy was 80 (interquartile range:
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40−103) seconds. Technical and procedural success was achieved in 77 (94%) and
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74 (90%) cases, respectively. Two (2.4%) Ellis Class 2 perforations occurred after IVL
use and were managed conservatively.
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Conclusion: IVL is increasingly being used in CTO PCI with encouraging outcomes.
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| INTRODUCTION

made to cross the lesion through a collateral vessel or bypass graft
supplying the target vessel distal to the lesion. Antegrade dissection/re‐

Severe coronary calcification is common and often increases the

entry was defined as antegrade PCI during which a guidewire was

difficulty of chronic total occlusion (CTO) percutaneous coronary

intentionally introduced into the extraplaque space proximal to or within

intervention (PCI).1,2 Calcification can hinder wire advancement and

the occlusion, or when re‐entry into the distal true lumen was attempted

penetration, as well as, equipment delivery and stent expansion.3

after intentional or inadvertent extraplaque guidewire crossing.

Intravascular lithotripsy (IVL) has been useful for treating calcification

Technical success was defined as successful CTO revascularization

in non‐CTO lesions,4,5 but the use of IVL in CTO PCI has received

with achievement of <30% residual diameter stenosis within the treated

limited investigation6‐8 and was the focus of the present study.

segment and restoration of TIMI grade 3 antegrade flow. Procedural
success was defined as the achievement of technical success without
any in‐hospital major adverse cardiac events (MACE). In‐hospital MACE

2

| MATERIALS AND METHODS

included any of the following adverse events prior to hospital discharge:
death, MI, recurrent symptoms requiring urgent repeat target‐vessel

2.1

| Patient population

revascularization with PCI or coronary artery bypass graft (CABG)
surgery, tamponade requiring either pericardiocentesis or surgery, and

We analyzed the baseline clinical and angiographic characteristics and

stroke. MI was defined using the Third Universal Definition of Myocardial

procedural outcomes of 82 CTO PCIs that required IVL performed at 14

Infarction (type 4a MI).11 The Japanese CTO (J‐CTO) score was

centers between 2020 and 2022 (Supporting Information: Table). Data

calculated as described by Morino et al.,12 the PROGRESS‐CTO score

collection was recorded in a dedicated online database (PROGRESS

as described by Christopoulos et al.13 and the PROGRESS‐CTO

CTO: Prospective Global Registry for the Study of Chronic Total

complications score as described by Danek et al.14

Occlusion Intervention; Clinicaltrials.gov identifier: NCT02061436).
Study data were collected and managed using REDCap (Research
Electronic Data Capture) electronic data capture tools hosted at
9,10

Minneapolis Heart Institute Foundation.

2.3

|

Statistical analysis

The study was approved

by the institutional review board of each center.

Categorical variables were expressed as percentages and compared
using the Pearson's χ2. Continuous variables are presented as mean ±
standard deviation or as median (interquartile range [IQR]) unless

2.2

| Definitions

otherwise specified and were compared using the student's t‐test for
normally distributed variables and the Wilcoxon rank‐sum test

Coronary CTOs were defined as coronary lesions with TIMI (thrombolysis

for nonparametric variables, as appropriate. Temporal trends were

in myocardial infarction) grade 0 flow of at least 3 months in duration.

tested for significance with linear contrast analysis (for continuous

Estimation of the duration of occlusion was clinical, based on the first

variables) and with the Cochran−Armitage test (for categorical variables).

onset of angina, prior history of myocardial infarction (MI) in the target

All statistical analyses were performed using JMP, version 16.0 (SAS

vessel territory, or comparison with a prior angiogram. Calcification was

Institute). A p < 0.05 was considered to indicate statistical significance.

assessed by angiography as mild (spots), moderate (involving ≤50% of the
reference lesion diameter), or severe (involving >50% of the reference
lesion diameter). Moderate proximal vessel tortuosity was defined as the

3

| RESULTS

presence of at least 2 bends >70° or 1 bend >90° and severe tortuosity as
2 bends >90° or 1 bend >120° in the CTO vessel. Blunt or no stump was

During the study period, IVL was used in 82 of 3301 (2.5%) CTO PCI

defined as lack of tapering or lack of a funnel shape at the proximal cap.

procedures (Figure 1A). Use of IVL increased from 0.4% in 2020 to

Interventional collateral vessels were defined as collateral vessels

7% in 2022 (p for trend < 0.001) (Figure 1B). The baseline clinical

considered amenable to crossing by a guidewire and a microcatheter by

and angiographic characteristics of the included patients are

the operator. A procedure was defined as retrograde if an attempt was

summarized in Table 1. Mean age was 69 ± 11 years, and 79.3% of
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TABLE 1

3

(Continued)
N = 82

Prior valve surgery/procedure

4 (4.9%)

Chronic lung disease

13 (15.9%)

Baseline creatinine (mg/dl)

1.03 (0.87−1.28)

Currently on dialysis

3 (3.7%)

CAD presentation
▪ Stable angina

56 (68.2%)

▪ Unstable angina

15 (18.3%)

▪ NSTEMI

4 (4.9%)

▪ STEMI

0 (0%)

▪ Non‐ischemic symptoms

3 (3.7%)

▪ No symptoms

4 (4.9%)

Angiographic characteristics
CTO target vessel

F I G U R E 1 (A) Overall intravascular lithotripsy use.
(B) Intravascular lithotripsy use over time. [Color figure can be viewed
at wileyonlinelibrary.com]

▪ RCA

44 (53.7%)

▪ LAD

16 (19.5%)

▪ LCX

19 (23.2%)

▪ Left main

2 (2.4%)

▪ Other

1 (1.2%)

“Interventional” collaterals

42 (51.2%)

Calcification (moderate/severe)

69 (84.1%)

Proximal vessel tortuosity (moderate/severe)

32 (39.0%)

Proximal cap ambiguity

24 (29.3%)

Distal cap at bifurcation

20 (24.4%)

Adequate distal landing zone

55 (67.1%)

Side branch at the proximal cap

34 (41.5%)

68.9 ± 10.7

Blunt/no stump

40 (48.8%)

65 (79.3%)

In‐stent restenosis

31 (37.8%)

Body mass index (kg/m )

31.9 ± 6.1

Prior attempt to open CTO

9 (11.0%)

Diabetes mellitus

51 (62.2%)

Vessel diameter (mm)

3.12 ± 0.51

Hypertension

78 (95.1%)

CTO length (mm)

30 (20−60)

Dyslipidemia

74 (90.2%)

J‐CTO score

2.75 ± 1.05

Left ventricular ejection fraction (%)

50 (39−59)

Progress CTO score

1.25 ± 1.01

Congestive heart failure

28 (34.1%)

Progress CTO complication score

3.57 ± 1.82

Prior myocardial infarction

35 (42.7%)

Prior PCI

50 (61.0%)

Prior CABG

30 (36.6%)

Cerebrovascular disease

11 (13.4%)

Peripheral arterial disease

14 (17.1%)

T A B L E 1 Clinical and angiographic characteristics and
procedural outcomes of the study patients
N = 82
Clinical characteristics
Age (years)
Male
2

(Continues)

Abbreviations: CABG, coronary artery bypass graft surgery;
CAD, coronary artery disease; CTO, chronic total occlusion; J, Japan;
LAD, left anterior descending artery; LCX, left circumflex artery;
NSTEMI, non‐ST segment elevation myocardial infarction;
PCI, percutaneous coronary intervention; PROGRESS, Progressive
Global Registry of Chronic Total Occlusion Interventions;
RCA, right coronary artery; STEMI, ST segment elevation myocardial
infarction.
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the patients were men. The prevalence of diabetes (62.2%),

balloon in 5 cases, with scoring balloon in 7 cases, with laser

hypertension (95.1%), dyslipidemia (90.2%), and prior CABG surgery

atherectomy in 3 cases, with rotational atherectomy in 7 cases and

(36.6%) was high.

with orbital atherectomy in 3 cases. The decision to use more than one

The most common CTO target vessel was the right coronary artery

calcium modification devices was made by the operator. During the

(53.7%), followed by the left circumflex artery (23.2%). Mean J‐CTO and

study period, 234 lesions (7.1%) were balloon undilatable and IVL was

PROGRESS‐CTO scores were 2.8 ± 1.1 and 1.3 ± 1.0, respectively, with

used in 26 of these (11.1%). Figure 3 illustrates the treatments used for

84.1% of the study lesions being moderately to severely calcified. IVL

balloon undilatable lesions with high‐pressure balloon inflation being the

was used in 10% of severely calcified lesions (Figure 2). IVL was

most common strategy (42.3%), followed by rotational atherectomy

combined with another calcium modification device (cutting balloon,

(28.6%) and cutting balloon.

scoring balloon, laser atherectomy, rotational atherectomy, or orbital

The procedural characteristics and outcomes of IVL‐facilitated CTO

atherectomy) in 25 cases (30.5%). IVL was combined with cutting

PCIs are shown in Table 2. A femoral‐radial approach was used in 48.8%
with a bifemoral approach used in 37.8% of the cases. Antegrade wiring
was used in 91.5% of the study CTOs and was the most common
successful crossing strategy (64.6%) followed by the retrograde approach
(22.0%). Intravascular ultrasound (IVUS) was used in 89% of the cases.
The indication for IVUS was stent optimization in 56 cases (76.7%), and to
assist crossing in 17 cases (23.3%) IVUS. Technical and procedural
success were achieved in 77 (94%) and 74 (90%) cases, respectively.
Median contrast volume, air kerma radiation dose, procedure time, and
fluoroscopy time were 150 (IQR: 100−220) ml, 1.8 (IQR: 1.2−3.5) Gray,
138 (IQR: 100−190)min, and 49 (IQR: 27−79) min, respectively.
The IVL data are presented in Table 3. The 3.5 mm diameter
lithotripsy balloon was the most commonly used balloon (28.1%),
followed by the 3.0 mm balloon (25.6%). The maximal lithotripsy
balloon inflation pressure that was applied was 4 atm in 29 (35.4%)
and 6 atm in 53 (64.6%) cases. The median number of lithotripsy runs

F I G U R E 2 Lithotripsy use among heavily calcified CTO lesions.
CTO, chronic total occlusion. [Color figure can be viewed at
wileyonlinelibrary.com]

per case was 8,4,10 and in most cases (62.2%), 10 pulses per
lithotripsy run were used. The median duration of lithotripsy was 80
(IQR: 40−103) seconds.

F I G U R E 3 Use of intravascular lithotripsy and other treatment modalities in balloon undilatable CTO lesions. CTO, chronic total occlusion.
[Color figure can be viewed at wileyonlinelibrary.com]
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TABLE 2
patients

Procedural characteristics and outcomes of the study

5

There were seven (8.5%) perforations: four Ellis class 2 and three
Ellis class 3. Only two (2.4%) Ellis Class 2 perforations were related to

N = 82

IVL use: they occurred after stent expansion with the IVL balloon and
were managed conservatively with anticoagulation reversal. The

Procedural characteristics

mechanism of the remaining five perforations was wire exit (3 cases)

Access

or stent induced (2 cases) and were treated either with pericardio-

▪ Bifemoral approach

31 (37.8%)

▪ Biradial approach

4 (4.9%)

prolonged balloon inflation (1 case). Three cases were complicated by

▪ Femoral‐radial approach

40 (48.8%)

equipment loss (1 stent loss, 1 balloon fracture, and 1 TrapLiner

▪ Single radial/femoral

7 (8.5%)

catheter shaft fracture). One patient with severe end stage

centesis (2 cases with tamponade), a covered stent (2 cases), or

cardiomyopathy had cardiac arrest and died.

Crossing strategies used
▪ Antegrade wiring

75 (91.5%)

▪ Retrograde

24 (29.3%)

▪ Antegrade dissection and re‐entry

10 (12.2%)

4 |

D IS CU SS IO N

To the best of our knowledge, our study is the largest to date

Successful crossing strategy

examining the use of IVL during CTO PCI. The major findings are the

▪ Antegrade wiring

53 (64.6%)

▪ Retrograde

18 (22.0%)

▪ Antegrade dissection and re‐entry

6 (7.3%)

balloon undilatable lesions; (3) CTO PCI success was high when IVL

▪ None

5 (6.1%)

was used; (4) the incidence of perforation related to IVL was

following: (1) IVL is used infrequently but its use has been increasing;

IVUS use

73 (89.0%)

Number of stents used

2.42 ± 0.92

(2) IVL is most commonly used for severely calcified lesions and

low (2.4%).
Coronary calcification can hinder CTO PCI by impairing wire

Procedural outcomes

advancement and penetration, affecting equipment delivery, and
preventing stent expansion.1,3 The presence of calcium has been

Technical success

77 (93.9%)

associated with lower technical success and higher risk of complica-

Procedural success

74 (90.1%)

tions2,15,16 highlighting the importance of preparation to prevent

Procedure time (min)

138 (100−190)

Fluoroscopy time (min)

49 (27−79)

Air kerma radiation dose (Gray)

1.8 (1.2−3.5)

Contrast volume (ml)

150 (100−220)

optimal stent expansion.18 In our study, IVL was used in 57 cases

MACE

3 (3.7%)

with severe calcification, and technical success was achieved in

Death

1 (1.2%)

Tamponade requiring pericardiocentesis

2 (2.4%)

associated with lower success and worse outcomes.19 The most

Perforation

7 (8.5%)

frequent treatments for balloon undilatable lesions are high pressure

Equipment loss

3 (3.7%)

balloon inflations,20 rotational atherectomy, laser,21 and cutting

periprocedural adverse events.17 As a device that delivers localized
pulsatile sonic pressure waves to circumferentially modify vascular
calcium, IVL can be used to disrupt and induce circumferential
fracture in calcific plaques, altering vessel compliance, and facilitating

94.7% of these cases.
Balloon undilatable lesions are common in CTO PCI and are

Abbreviations: IVUS, intravascular ultrasound; MACE, major adverse
cardiac events.

balloons.22 IVL had also been used off‐label for balloon undilatable
CTOs. Recently, Rola et al.8 reported five heavily calcified balloon
undilatable CTO lesions treated successfully with IVL; the IVL balloon

TABLE 3

Intravascular lithotripsy data of the study cases
N = 82

Lithotripsy balloon diameter (mm)

3.5 (3.0−3.8)

ruptured in 1 case without adverse consequences to the patient. In
our cohort, the prevalence of balloon undilatable lesions was 7.1%
and IVL was used successfully in all of them.
In balloon undilatable CTO lesions, we recommend a stepwise
approach to lesion preparation (Figure 4). Upfront atherectomy is

Max lithotripsy balloon inflation pressure

preferred in heavily calcified lesions that are unlikely to respond to

▪4 atm

29 (35.4%)

▪6 atm

53 (64.6%)

decision.18,23 Zhang et al.18 developed an IVUS‐based calcium score

Total number of lithotripsy runs

8 (4−10)

with upfront use of calcium modification devices recommended in

Pulses per lithotripsy run

32.8 ± 32.1

lesions with two or more of the following: (1) superficial calcium angle

Total duration of lithotripsy (second)

80 (40−103)

balloon angioplasty. Use of intravascular imaging can help facilitate this

>270° longer than 5 mm; (2) 360° of superficial calcium; (3) calcified
nodule; and (4) vessel diameter <3.5 mm. Similarly, Fujino et al.23

6
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F I G U R E 4 Algorithm for approaching
de‐novo balloon undilatable lesions. CABG,
coronary artery bypass graft surgery; IVL,
intravascular lithotripsy; SIS OPN, very high‐
pressure balloon. [Color figure can be viewed at
wileyonlinelibrary.com]

F I G U R E 5 Intravascular ultrasound images
from the same section of a calcified CTO lesion.
(A) Before intravascular lithotripsy use. (B) After
intravascular lithotripsy use, showing calcium
fracture and lumen enlargement. CTO, chronic
total occlusion. [Color figure can be viewed at
wileyonlinelibrary.com]

created a calcium scoring system based on optical coherence tomogra-

vessel preparation prior to stent implantation as described above

phy (OCT) giving 2 points for maximum calcium angle >180°, 1 point for

(Figure 5, Supporting Information: Video 1, 2).3,26

maximum calcium thickness >0.5 mm, and 1 point for calcium length

In the present study, IVL was used in 2.5% of CTO PCIs, with

>5 mm. Lesions with a score of 4 had higher risk of underexpansion and

increasing use over time, and was associated with high technical

could benefit from upfront use of calcium modification.

(94%) and procedural (90%) success. Oksnes et al.7 analyzed 55

In most calcified lesions noncompliant balloons (sized 1:1 to the

CTO PCI cases (5.2%) treated with IVL and reported high technical

target vessel) inflated at high pressure are initially used, followed by

(96%) and procedural (93%) success rates and low perforation rate

plaque modification balloons, atherectomy (rotational, orbital, laser),

(5%) related to IVL. IVL was used commonly (in 53% of cases vs.

IVL, the very high‐pressure balloon or extraplaque lesion crossing,

31% in our study) in combination with another calcium modifica-

and extraplaque modification. The combination of atherectomy with

tion device.

IVL can also be considered for both balloon uncrossable and balloon

The Disrupt CAD III study (Disrupt Coronary Artery Disease)5

undilatable lesions. CABG may be needed if the lesion fails to expand.

evaluated the safety and effectiveness of IVL in severely calcified

IVUS was used in 73 of the IVL cases (89%) in our study.

coronary lesions. This prospective, single‐arm multicenter study

Intravascular imaging (IVUS or OCT) is essential for calcium vessel

showed that IVL can safely and effectively facilitate stent delivery

assessment during CTO PCI24,25 as it can determine the location

and expansion in patients with severely calcified coronary lesions and

(superficial or deep), as well as the morphology and the degree of

with an in‐hospital MACE rate of 7% and a perforation rate of 0.3%.

calcification of the proximal cap.3,18 After crossing the CTO lesion,

In our cohort, the in‐hospital MACE rate was lower (3.7%) but the

intravascular imaging can help assess the distribution of calcium,

perforation rate was slightly higher (2.4%), although only 2 of 7

determine the need for calcium modification, and confirm adequate

perforations were related to IVL use.

KOSTANTINIS
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